The Latest Breaking News from WHO

Other Lives: Session bass guitarist who played on many hit singles and albums

Systematic reviews and meta-analyses have found that across ailments, population groups, study types, and treatment regimes, homoeopathic treatments lack clinically significant effects

A WHO, UNICEF, UNFPA paper titled ‘Improving maternal and newborn health and survival and reducing stillbirth progress report 2023’, observed that India’s share of the total maternal and newborn deaths and stillbirths was about 17%. Both newborns and women are extremely vulnerable in the hours and days after birth and therefore…

GMP comprises mandatory standards that build and bring quality to products by way of control on materials, methods, machines, processes, personnel, and facility or environment, etc. The GMP system was first incorporated in 1988 in Schedule M of the Drugs and Cosmetics Rules, 1945, and the last amendment was done…

Cells taken in 1951 from Lacks, a Black woman, without her knowledge became the cornerstone of modern medical research.

As the planet warms thanks to climate change, tropical storms are becoming more frequent, more powerful, and wetter

WHO adds polypills to EML 2023, a major policy change. Clinical evidence shows polypills reduce risk of cardiovascular events, incl. heart attack & stroke. Salim Yusuf, a Keralite, spent two decades building evidence for polypill's safety & efficacy. Polypill reduces risk by 40-50%. Govts. should purchase & provide polypill at…

Can you only work out on the weekends? New research shows shows that on most health metrics, it’s about cumulative time instead of regularity.

The article discusses the alarming surge in dengue cases globally, with regions like America, Europe, and the Middle East reporting significant outbreaks in 2023. Dengue, caused by the dengue virus with four serotypes, poses a significant health challenge due to global warming favoring disease-transmitting mosquitoes. Efforts to control the disease…

A randomized phase-3/4 trial conducted in India to assess a short-course treatment for pre-XDR TB or treatment intolerant/non-responsive MDR pulmonary TB has shown promising results. The trial used a combination of three drugs (bedaquiline, pretomanid, and linezolid) for a duration of 26 weeks, resulting in higher treatment adherence and an…

Big Tech Suppressed Highly Effective Technology to Prevent Spread of Covid-19, Costing Countless Lives